[
  {
    "ts": null,
    "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
    "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
    "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765305600,
      "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
      "id": 137749832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
      "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech: Maintaining \"Strong Buy\" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart",
    "summary": "BioNTech stock is a \"Strong Buy\", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=5783584119cffb601eb58492ea4e972340515254eace6399b29cbe2e717b3bc0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765302863,
      "headline": "BioNTech: Maintaining \"Strong Buy\" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart",
      "id": 137743809,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242604824/image_2242604824.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BioNTech stock is a \"Strong Buy\", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=5783584119cffb601eb58492ea4e972340515254eace6399b29cbe2e717b3bc0"
    }
  },
  {
    "ts": null,
    "headline": "Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play",
    "summary": "Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.",
    "url": "https://finnhub.io/api/news?id=b32efa5d8aab9d5ebaec26e9d547a7993eab875082cd6437630779d76bd8ddf2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765296720,
      "headline": "Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play",
      "id": 137742781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.",
      "url": "https://finnhub.io/api/news?id=b32efa5d8aab9d5ebaec26e9d547a7993eab875082cd6437630779d76bd8ddf2"
    }
  },
  {
    "ts": null,
    "headline": "Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb",
    "summary": "The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a",
    "url": "https://finnhub.io/api/news?id=96338e445ef0d15113a47f0fd5daf51bbc8e1ebf5744e5557f3cc8964b1e7c2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765292280,
      "headline": "Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb",
      "id": 137742694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a",
      "url": "https://finnhub.io/api/news?id=96338e445ef0d15113a47f0fd5daf51bbc8e1ebf5744e5557f3cc8964b1e7c2d"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech, Bristol Myers Report Early Breast Cancer Tumor Response Data for Experimental Antibody Treatment",
    "summary": "BioNTech (BNTX) said Tuesday it and Bristol Myers Squibb (BMY) reported interim phase 2 data showing",
    "url": "https://finnhub.io/api/news?id=390d0177e1b88e8ae4756e6a58646e87a723559236189ede5f1c01ea9bc14f58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765290248,
      "headline": "BioNTech, Bristol Myers Report Early Breast Cancer Tumor Response Data for Experimental Antibody Treatment",
      "id": 137740319,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BioNTech (BNTX) said Tuesday it and Bristol Myers Squibb (BMY) reported interim phase 2 data showing",
      "url": "https://finnhub.io/api/news?id=390d0177e1b88e8ae4756e6a58646e87a723559236189ede5f1c01ea9bc14f58"
    }
  },
  {
    "ts": null,
    "headline": "Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer",
    "summary": "MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).",
    "url": "https://finnhub.io/api/news?id=a7e4d9343a9e5f5495c6c8ca3af18095dc62604cf691f2f06bb802cc1da57cb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765284300,
      "headline": "Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer",
      "id": 137740091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).",
      "url": "https://finnhub.io/api/news?id=a7e4d9343a9e5f5495c6c8ca3af18095dc62604cf691f2f06bb802cc1da57cb5"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer",
    "summary": "Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patientsPumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespective of PD-L1 expression levelsData highlight the potential of pumitamig for patients wit",
    "url": "https://finnhub.io/api/news?id=2fe4c93a8c15b9f51b8d8b5bfa9b22b733487697a8c9b31003cf06f298044fb8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765281600,
      "headline": "BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer",
      "id": 137740321,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patientsPumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespective of PD-L1 expression levelsData highlight the potential of pumitamig for patients wit",
      "url": "https://finnhub.io/api/news?id=2fe4c93a8c15b9f51b8d8b5bfa9b22b733487697a8c9b31003cf06f298044fb8"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Cheap For A Reason",
    "summary": "Bristol-Myers Squibb faces patent cliff risks despite strong drug revenues and a 4.8% yield. Click here to read my latest analysis of BMY stock.",
    "url": "https://finnhub.io/api/news?id=c611882e7fc126770626564e86a81305701da9a1e1cceda8f0018edbb3f247ed",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765274453,
      "headline": "Bristol-Myers Squibb: Cheap For A Reason",
      "id": 137740833,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160008492/image_2160008492.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb faces patent cliff risks despite strong drug revenues and a 4.8% yield. Click here to read my latest analysis of BMY stock.",
      "url": "https://finnhub.io/api/news?id=c611882e7fc126770626564e86a81305701da9a1e1cceda8f0018edbb3f247ed"
    }
  },
  {
    "ts": null,
    "headline": "1 Large-Cap Stock on Our Buy List and 2 We Turn Down",
    "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
    "url": "https://finnhub.io/api/news?id=405cf65a2345d106e239ea9f625dd529b10618186c7bbee98338cf469c0e2e22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765255028,
      "headline": "1 Large-Cap Stock on Our Buy List and 2 We Turn Down",
      "id": 137740322,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
      "url": "https://finnhub.io/api/news?id=405cf65a2345d106e239ea9f625dd529b10618186c7bbee98338cf469c0e2e22"
    }
  }
]